Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that data from scientific studies related to the screening efficacy of the EyeArt® AI Eye...
Takeda’s Phase 3b head-to-head study comparing Entyvio to AbbVie’s Humira, as well as preliminary results of an ongoing post-marketing requirement study for Pfizer’s Xeljanz regarding safety are beginning to affect gastroenterologists’...
INNATE PHARMA ENROLLS FIRST PATIENT IN IPH4102 TELLOMAK PHASE II STUDY TELLOMAK is a Phase II study to evaluate the efficacy of IPH4102 in different subtypes of T-cell lymphoma The TELLOMAK trial design and preclinical data in PTCL will be presented at the...
Independent Dose Escalation Committee (DEC) recommends continuing the study at an increased dose Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the...
Dr. Mohammed is a Professor of Cancer Biology at the Department of Comparative Pathobiology, Purdue Center for Cancer Research, and Indiana University School of Medicine. Image Credit: Cannabis Science Cannabis Science, a U.S. company specializing in the development...
–First-in-Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GFB-887, a Targeted Podocyte-protective Therapeutic for the treatment of Focal Segmental Glomerulosclerosis, Treatment-resistant Minimal Change Disease and Diabetic...
Email
Text